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Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide,
characterized by clinical aggressiveness, resistance to conventional chemotherapy, and
high lethality. Consequently, there is an urgent need to better delineate the molecular
pathogenesis of HCC to develop new preventive and therapeutic strategies against
this deadly disease. Noticeably, emerging evidence indicates that proteins involved in
lipid biosynthesis are important mediators along the development and progression of
HCC in humans and rodents. Here, we provide a comprehensive overview of: (a) The
pathogenetic relevance of lipogenic proteins involved in liver carcinogenesis, with a
special emphasis on the master fatty acid regulator, fatty acid synthase (FASN); (b) The
molecular mechanisms responsible for unrestrained activation of FASN and related fatty
acid biosynthesis in HCC; (c) The findings in experimental mouse models of liver cancer
and their possible clinical implications; (d) The existing potential therapies targeting FASN.
A consistent body of data indicates that elevated levels of lipogenic proteins, including
FASN, characterize human hepatocarcinogenesis and are predictive of poor prognosis of
HCC patients. Pharmacological or genetic blockade of FASN is highly detrimental for the
growth of HCC cells in both in vitro and in vivo models. In conclusion, FASN is involved
in the molecular pathogenesis of HCC, where it plays a pivotal role both in tumor onset
and progression. Thus, targeted inhibition of FASN and related lipogenesis could be a
potentially relevant treatment for human HCC.
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INTRODUCTION: HUMAN HEPATOCELLULAR CARCINOMA
Human hepatocellular carcinoma (HCC) is one of the most frequent and pernicious solid tumors,
ranking fifth in incidence and second in lethality worldwide (1–3). Albeit the prevalence of HCC
is highest in Eastern Asia and sub-Saharan Africa, where the HBV chronic infection is endemic
and the food is contaminated by the mycotoxin aflatoxin B1, its incidence is rapidly rising also in
Western Europe and North America (1–3). In the latter areas, however, this escalation in HCC
occurrence cannot be entirely explained by the established causal relationship linking chronic
hepatitis B or C infection, or ethanol consumption, to hepatocarcinogenesis. Indeed, at least one
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quarter of HCC cases remains idiopathic (1–3). In the last decade,
non-alcoholic fatty liver disease (NAFLD) has emerged for its
potential etiopathogenetic role in liver cancer development,
especially in industrialized countries. Numerous case-control
studies indicate in fact that HCC patients with cryptogenic
cirrhosis display clinical and demographic characteristics
suggestive of NAFLD, when compared with HCC patients of
viral or alcoholic etiology (3–6). In particular, it has been shown
that the increased incidence of HCC in the United States over
the past few decades has occurred in parallel with the epidemic
of NAFLD (3–6). The latter condition is characterized by the
excessive accumulation of lipids in the liver and is associated with
obesity, insulin resistance, and type 2 diabetes, often evolving
into HCC (3–6).
Regardless of the causative agent, most HCC patients
are diagnosed with an advanced disease, precluding the
employment of potentially curative therapies, including
liver transplantation or partial liver resection (1–3). In
addition, molecularly based treatments provided negligible
benefits in terms of survival in HCC patients, with the
multi-kinase inhibitors Sorafenib and Regorafenib being
the only drugs able to extend the life expectancy by ∼2/3
months (7–9). Consequently, new therapeutic approaches
aimed at restraining the growth of advanced HCC are highly
needed. For this purpose, the molecular pathogenesis of
HCC should be better elucidated to identify critical targets
whose inhibition might hamper liver tumor development
and/or progression.
THE “LIPOGENIC PHENOTYPE”
Deregulated lipid biosynthesis (commonly referred to as “de
novo lipogenesis” or “de novo lipid synthesis”) plays an
important pathogenetic role in the development of various
metabolic diseases, such as diabetes mellitus, obesity, and the
metabolic syndrome. In addition, emerging evidences indicate
that metabolism reprogramming, including aberrant lipogenesis,
is a widespread phenomenon in most cancer types (10–12).
From the historical point of view, the scientific work of the
German biochemist and Nobel Prize laureate Otto Warburg,
who has been dealing with this issue for several decades since
the 1920s, can be considered a pioneer work in this field
(13, 14). The starting point was his observation that tumor
cells metabolize glucose into lactate under aerobic conditions,
while not using the energetically more plausible route of
oxidative decarboxylation by the citric acid cycle for energy
production. This observation is nowadays well-known as the
“Warburg effect” or “Warburg phenomenon” (13, 14). One
plausible explanation for this apparently paradoxical event is
that glycolysis, although significantly less efficient for energy
production than aerobic decarboxylation, can produce adenosine
triphosphate (ATP) about 100 times faster than mitochondrial
respiration would (14). Consequently, the tumor cell can provide
sufficient energy for the accelerated metabolic processes along
carcinogenesis. In addition, through the Warburg phenomenon,
a reservoir of important metabolic intermediates available for
amino acid synthesis and pentose phosphate production—
indispensable prerequisites for ensuring adequate protein and
DNA synthesis—is generated (14). Furthermore, elevated aerobic
glycolysis results in a growth advantage for the most proliferating
tumor cells within their microenvironment (14). The immediate
consequence of increased glycolysis is the accumulation of the
pyruvic acid (pyruvate) metabolite. While most of the pyruvate
is converted into lactate and eliminated via the cell membrane,
some of the pyruvate is instead converted to acetyl-CoA. In
contrast to the normal cell, acetyl-coA represents the primary
substrate of the de novo lipid synthesis in tumor cells (14).
As normal tissues can cover most of their lipid requirements
via dietary lipids coming from the blood circulation, de novo
lipogenesis does not play a significant role in the metabolism of
these cell types; as a result, the expression of lipogenic enzymes
is low (10–12). In striking contrast, a universal up-regulation
of lipid synthesis occurs in tumor cells (10–12). Importantly,
the latter phenomenon is only occasionally associated with a
change in cellular morphological properties that are detectable
by light microscopy (namely, lipid accumulation in tumor cells
that, consequently, appear enlarged, and with a clear cytoplasm)
(10–12). Most frequently, indeed, aberrant lipogenesis results in
marked alterations of various molecular andmetabolic processes,
including intracellular signal transduction, and gene expression.
At the molecular level, increased lipogenesis is primarily
recognizable by the fact that numerous enzymes involved in lipid
metabolism (lipogenic enzymes) display strong activity and high
expression in tumor cells (10–12). In particular, this refers to
the coordinated upregulation of the key enzymes involved in the
conversion of glucose into fatty acids, such as ATP citrate lyase
(ACLY), acetyl-CoA carboxylase (ACAC), fatty acid synthase
(FASN), malate enzyme (ME), and stearoyl-CoA-desaturase 1
(SCD1). Each of these enzymes exhibits a pivotal function in the
series of events leading to aberrant lipid biosynthesis. Specifically:
(a) ACLY converts citrate from the citrate cycle to acetyl-CoA;
(b) ACAC synthesizes malonyl-CoA starting from acetyl-CoA;
(c) FASN, starting from malonyl-CoA and consuming acetyl-
CoA and NADPH, synthesizes the saturated fatty acid palmitate
(palmitic acid) and other saturated long-chain fatty acids; (d) ME
catalyzes the production of the reducing NADPH necessary for
the synthesis of long-chain fatty acids; and (e) SCD1 converts
saturated fatty acids into unsaturated fatty acids, which serve
as substrates for the synthesis of triglycerides, cholesterol esters,
and phospholipids (10–12, 14, 15). The major steps of de novo
lipogenesis are summarized in Figure 1.
The requirement of lipids for proliferating tumor cells is high
for several reasons. First, lipids represent the building blocks
necessary for cell membrane production and, consequently, cell
duplication (10–12, 14, 15). Second, the newly synthesized fatty
acids are used, if needed, to provide additional energy through
the β-oxidation. Third, lipids serve as anchors for selective
protein transport to the membrane and as precursors for the
synthesis of “lipid second messenger” molecules (10–12, 14, 15).
Based on these data, it is obviously not surprising that most
epithelial tumors exhibit an increased de novo lipid synthesis
and an associated upregulation of the lipogenic enzymes. These
include carcinomas of the breast, colorectal, prostate, urinary
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FIGURE 1 | Simplified representation of de novo lipogenesis in the tumor cell. ACC, acetyl-CoA carboxylase; ACLY, adenosine triphosphate citrate lyase; FASN, fatty
acid synthase; GLUTs, glucose transporters; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SCD1, stearoyl-CoA desaturase 1. Detailed
description of the pathway is reported in the main text.
system, ovary, upper gastrointestinal tract, lung, and oral
cavity (10–12). Furthermore, it is well-established that tumor
cells display increased ACLY expression and activity. Of note,
suppression of ACLY by either small interfering RNA molecules
(siRNAs) or the pharmacological inhibitor SB-204990 blunts
the proliferation and survival of carcinoma cells both in vitro
and in vivo (16). These intriguing findings are in line with the
observation that ACAC, FASN, and SCD1 are up-regulated in
numerous malignancies at both the transcriptional and protein
level, and their inactivation by treatment with specific siRNAs
or small molecular inhibitors significantly restrains tumor cell
proliferation and survival (10–12, 14, 15). Altogether, these data
suggest that de novo lipid synthesis as well as the activation of
lipogenic proteins and enzymes are critical for the growth of
tumor cells.
FATTY ACID SYNTHASE IN PHYSIOLOGY
AND CANCER
As reported above, fatty acid synthase (FASN) is the critical
enzyme responsible for de novo fatty acid synthesis (10–12).
Specifically, FASN catalyzes the reaction leading to the generation
of palmitate and 16-carbon long fatty acid from acetyl-CoA
and malonyl-CoA (10–12). Palmitate is a 16 carbon saturated
fatty acid that is a major component of cell membranes and
human breast milk, and is incorporated into triglycerides for
energy storage. In addition, palmitate is a substrate in the
palmitoylation of membrane proteins and acts as a precursor
in the synthesis of complex lipids, including cholesterol and
glycerophospholipids (10–12).
FASN consists of seven functional domains: acyl carrier
protein, malonyl/acetyltransferase, ketoacyl synthase, ketoacyl
reductase, dehydrase, enoyl reductase, and thioesterase (17,
18). In humans, FASN is encoded by the FASN gene and
composed of two identical 272 kDamultifunctional polypeptides,
in which the seven domains form a single bond (17).
The human FASN gene locus is located at chromosome 17
(17q25.3) (10).
FASN is mainly expressed in the cytosol of healthy liver,
adipose, brain, cycling endometrium, and lactating mammary
gland cells; in these tissues and organs, lipogenesis is a crucial
physiological process (10–12).
In cancer, multiple studies have shown that FASN is strongly
upregulated in tumors from breast, prostate, colorectal, bladder,
ovary, and lung, especially when characterized by clinical
aggressiveness, poor prognosis, and resistance to therapy. In
contrast, corresponding non-tumor tissues adjacent to the tumor
generally express low levels of FASN protein (10–12). However,
increased FASN expression has also been detected in some benign
and pre-neoplastic lesions of the prostate, breast, lung, stomach,
colon, and cutaneous nevi (10–12). Furthermore, investigations
conducted in breast, pancreatic, and colorectal tumors showed
that cancer patients exhibit elevated levels of FASN in the serum.
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Once again, FASN levels in patients’ serum directly correlate with
an adverse outcome (10–12).
Additional evidence linking FASN to cancer comes
from experimental models. For instance, in vitro ectopic
overexpression of FASN in breast cancer cells was found to
promote lipogenesis along with augmented cell growth and
proliferation (19). Also, transgenic overexpression of Fasn in
mice triggered the development of prostate epithelial neoplasia,
albeit it was not sufficient to induce invasive tumors per se
(20). Further studies with immortalized prostate epithelial cells
(iPrEC) suggested that, in addition to the Fasn expression,
co-expression of androgen receptor was required for invasive
adenocarcinoma development (20). Altogether, this body
of evidence indicates a unique association between FASN
expression and tumor development and/or progression.
FATTY ACID SYNTHASE IN
HEPATOCELLULAR CARCINOMA:
EVIDENCE FROM HUMAN DISEASE AND
EXPERIMENTAL MODELS
The contribution of unrestrained lipogenesis to the development
of hepatocellular carcinoma (HCC) and its progression as well
as the molecular mechanisms contributing to the aberrant
lipid biosynthesis are starting to be understood. Despite the
mounting evidence concerning the importance of aberrant
lipid biosynthesis in carcinogenesis, the first studies on this
phenomenon in human HCC are relative recent. In a small
study (21), overexpression of the mRNA of the main lipogenic
enzymes (FASN, ACAC, ACLY and SCD1) was described in
HCC when compared with non-neoplastic liver counterparts.
In addition, the sterol regulatory element-binding protein 1
transcription factor (SREBP1), a major inducer of lipogenesis,
has been identified as a negative prognostic factor in liver cancer
(22). Also, an in vitro study demonstrated that inhibition of
FASN significantly affects the growth of human HCC cell lines
in a p53-independent manner (23). Based on these intriguing
observations, several studies into the pathogenetic relevance of de
novo lipid synthesis in humanHCChave been initiated, especially
focusing on the molecular pathways that drive this event.
In a pioneering investigation, we analyzed the levels of the
critical lipogenic proteins in a large human HCC collection
(24). In particular, the HCC cohort used could be differentiated
into two distinct subgroups based on patient survival after
partial liver resection: a group of HCC with less aggressive
biological behavior or HCCB (defined as survival longer than
3 years) and one with higher aggressive behavior or HCCP
(defined as survival time shorter than 3 years) (24). Intriguingly,
a simultaneous upregulation of all relevant enzymes of the
lipogenic metabolismwas observed in HCCwhen compared with
non-tumorous surrounding liver tissues (24). These included the
enzymes responsible for fatty acids production (FASN, ACAC,
ACLY, ME, and SCD1) as well as the enzymes for cholesterol
biosynthesis [SREBP2, 3-hydroxymethylglutaryl-CoA reductase
(HMGCR), mevalonate kinase (MVK), and squalene synthetase
(SQS)]. Concomitantly, their upstream inducers [carbohydrate-
responsive element-binding protein (chREBP), SREBP1, liver
X receptor β (LXR-β)] were upregulated. Of note, the highest
levels of lipogenic enzymes were detected in HCC with poorer
prognosis (HCCP) (24). It is noteworthy to underline that the
content of the chemical end products of the respective lipid
synthesis (fatty acids, triglycerides, and cholesterol) changed in
an analogous manner (24). Thus, these data indicate increased
lipogenesis during development and progression of HCC in
humans. Subsequent investigations showed that the induction of
unrestrained lipogenesis was the result of both transcriptional
and post-transcriptional mechanisms (24). Specifically, in
addition to the aforementioned transcription factors (chREBP,
SREBP1, and LXR-β), we detected a prominent induction of
the ubiquitin-specific peptidase 2a (USP2a) (24). This protein is
involved in the inhibition of proteasome-induced degradation
of FASN, thus inducing stabilization and increased half-life of
the latter (25). Similarly, v-akt murine thymoma viral oncogene
homologous (AKT) was found to inhibit the ubiquitination of
SREBP1 by phosphorylation-dependent mechanisms (24). These
findings indicate that presumably a complex program involving
several pathways converge to increase lipid biosynthesis in
human HCC.
Since it is established that the AKT/mTOR pathway is a
prominent inducer of de novo lipogenesis in various tissues
and organs (26, 27), our group investigated whether this also
applies to human HCC. As expected, an increased induction
of activated (phosphorylated) AKT, mTOR, and the mTOR
effector RPS6, was detected from surrounding liver tissues to
HCC, especially HCCP, when compared to normal liver (24).
The importance of the AKT/mTOR signaling in lipogenesis
was further substantiated in human HCC cell lines, where
overexpression of myristoylated/activated AKT led to a rapid
increase in cell growth and a reduction in apoptosis. This
change in proliferation kinetics was paralleled by a sharp increase
in lipid synthesis and up-regulation of lipogenic enzymes
in AKT-overexpressing cells (24). Conversely, there was a
robust inhibition of cell growth associated with a decrease
in lipogenesis and a reduction in the content of lipogenic
proteins when AKT was selectively suppressed in HCC cell
lines (24). At the molecular level, activation of lipogenesis
was dependent on an intact mTOR complex1 (mTORC1)/RPS6
signaling pathway, as the addition of the mTORC1 inhibitor
rapamycin or the targeted inactivation of RPS6 by specific
siRNA impaired cell growth in the same cell lines (24). The
functional importance of the AKT/mTOR pathway in HCC
aberrant lipogenesis and FASN induction was substantiated in
a recent investigation from Zhao et al. (28). These authors
confirmed the relationship between FASN and the AKT/mTOR
cascade in HCC cell lines; furthermore, they identified the loss
of the microRNA (miR) 1207-5p as a critical mechanism leading
to unconstrained AKT/mTOR signaling pathway and FASN
activity in human liver cancer (28). Alternatively, activation of
the AKT/mTOR/FASN axis might be triggered by upregulation
of the basigin/CD147 protooncogene, a molecular event often
detected in human hepatocarcinogenesis (29, 30). Taken together,
these data indicate that the AKT/mTOR pathway plays a
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leading role in the activation of lipogenesis in human HCC.
The identified molecular mechanisms triggering unrestrained
FASN activity and lipogenesis in HCC are summarized
in Figure 2.
In light of these important premises, we determined
the requirement of FASN and de novo lipogenesis in
hepatocarcinogenesis in vivo, using genetic approaches. To
achieve this goal, we employed conditional FASN knockout
(KO) mice (31) and various oncogene driven HCC models,
such as AKT and AKT/c-Met mice. Previous data from our
group showed that hydrodynamic transfection of an activated
form of AKT (myristoylated/myr-AKT) triggers upregulation of
FASN, aberrant de novo lipid synthesis, and HCC development
after long latency in mice (24). To determine whether FASN
expression is necessary for myr-AKT driven liver tumor
development, we hydrodynamically injected myr-AKT and Cre
recombinase (AKT/Cre mice) into conditional FASNfl/fl mice
(32). Of note, while AKT overexpression in control mice resulted
in HCC development within 22–28 weeks post-injection,
none of the AKT/Cre mice exhibited pre-neoplastic and
neoplastic lesions. Equivalent results were achieved following
overexpression of myr-AKT in liver-specific FASN KO mice
(AlbCre; FASNfl/flmice) (32). The anti-neoplastic effect resulting
from FASN ablation in AKT/Cre mice was presumably due to
the downregulation of rapamycin-insensitive companion of
mTOR (Rictor), the critical member of the mammalian target
of rapamycin complex 2 (mTORC2) (27), which is responsible
for activation of the AKT protooncogene via phosphorylation.
The relevance of Rictor in this process was further demonstrated
by the finding that genetic depletion of Rictor in hepatocytes
prevented myr-AKT driven hepatocarcinogenesis in mice (32).
The crucial role of FASN in hepatocarcinogenesis has been
confirmed in a second mouse model, where myr-AKT was
co-transfected with the protooncogene c-Met (AKT/c-Met
mice). In this model, the co-expression of AKT and c-Met was
found to dramatically accelerate HCC development in mice
when compared to those transfected with AKT or c-Met alone,
with all AKT/c-Met mice being required to be euthanized
within 8 weeks post-injection due to high tumor burden
(33). Thus, AKT, c-Met, and Cre plasmids were transfected
into FASNfl/fl mice, allowing the simultaneous expression
of AKT and c-Met oncogenes, while deleting FASN in the
same subset of mouse hepatocytes (AKT/c-Met/Cre) (33).
Once again, genetic inactivation of FASN completely blunted
AKT/c-Met-driven hepatocarcinogenesis in AKT/c-Met/Cre
mice, implying that although extremely aggressive, AKT/c-Met
tumors fully depend on FASN activity to develop (33). Similar
results were obtained more recently by Guri et al. (34). These
authors generated a mouse model consisting of lack of Tsc1
and Pten tumor suppressor genes, which inhibit the mTORC1
and mTORC2 pathways, specifically in the liver (termed L-dKO
mouse). In these mice, liver-specific activation of the mTOR
signaling cascade promoted fatty acid synthesis, liver steatosis,
and HCC development. Noticeably, either treatment with the
FASN inhibitor Orlistat or Fasn knockdown using adenovirus
associated virus suppressed hepatocarcinogenesis in L-dKO
mice (34).
Altogether, the present data indicate that FASN and
related fatty acid biosynthesis play a critical pathogenetic role
in hepatocarcinogenesis.
INHIBITION OF FATTY ACID SYNTHASE IN
HUMAN HEPATOCELLULAR CARCINOMA:
IS IT A FEASIBLE OPTION?
Based on the body of evidence presented before, it can be
envisaged that FASN inhibition might represent a potentially
effective therapeutic strategy against human HCC (35). Several
FASN inhibitors have been tested against cancer in preclinical
studies, including cerulenin, Orlistat, C75, Fasnall, TVB-
2640, and others (Figure 3). However, only TVB-2640 is
currently under evaluation, alone or in combination with
other medications, in clinical trials against human cancers, not
comprising HCC (Table 1).
Pioneering examples of studies investigating the lipogenic
dependency of cancer in recent years include those performed
with small molecule FASN inhibitors like cerulenin, an antibiotic
isolated from fungal extracts. Cerulenin was found to be
active against numerous cancer cell lines and xenograft models;
however, the highly reactive nature of the cysteine-reactive
epoxide group and off-target activities hampered its clinical
application (36). In particular, activation of β-oxidation and
excessive energy expenditure, leading to weight-loss or anorexia,
represented the major factors limiting the application of
cerulenin in humans (35). Similar reasons prevented the
clinical use of C-75, a synthetic inhibitor of FASN, which was
also demonstrated to possess profound antineoplastic effects
in experimental models, and to enhance radiation-induced
apoptosis in prostate cancer cells, promoting cell cycle arrest in
the G2/M phase (37–39).
Orlistat is an anti-obesity drug, which acts by blocking the
absorption of free fatty acids from the gastrointestinal tract
through the inhibition of pancreatic and gastric lipase that
hydrolyze triglycerides (40, 41). Specifically, Orlistat possesses
a highly reactive beta-lactone that covalently captures reactive
serine residues in the FASN thioesterase domain (42). Despite its
potency in restraining the growth of in vitro and in vivo cancer
models (43, 44), the off-target activities together with the poor
water solubility and gastrointestinal absorption have hindered
the use of Orlistat as anti-tumor agent in patients (45).
C93 is one of the first inhibitors synthesized, which showed
antineoplastic activity initially in lung cancer cell lines, and
subsequently in trophoblastic neoplasias (46, 47), but no
significant further studies were recently performed. Fasnall, a
thiophenopyrimidine-based FASN inhibitor with potent and
broad antitumor activity against various breast cancer models,
might represent a promising alternative. Fasnall inhibits the
FASN capacity to facilitate the production of phospholipids
with saturated acyl chains, whereas it promotes the uptake of
exogenous unsaturated fatty acids, with consequent alterations
in signal transduction messages and promotion of apoptosis. Of
note, Fasnall have been shown to act synergistically to prolong the
survival of mouse models of breast cancer when associated with
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FIGURE 2 | Schematic representation of the identified molecular mechanisms triggering unrestrained fatty acid synthase (FASN) activity in hepatocellular carcinoma
cells. (A) Positive signals inducing activation of the AKT/mTOR pathway (CD147) and loss of negative stimuli (mIR 1207-5p) toward the same pathway lead to
activation of FASN and induction of its multiple, pro-oncogenic biologic effects, which are blunted by FASN inhibitors (B). Further details are reported in the text.
the chemotherapeutic agent carboplatin; in this study Fasnall was
well tolerated, with no changes in feeding behavior or weight
loss being detected in these mice, further suggesting its possible
application in the clinical practice (48).
Other high potential FASN inhibitors have been recently
developed. Among them, TVB-3166 is a imidazopyridine-
based, orally-available, FASN inhibitor, which suppresses
de novo palmitate synthesis in vitro and in vivo, and displays
antineoplastic activity in several experimental cancer models
(49, 50). The mechanism of action of TVB-3166 on aberrant
lipogenesis resides on its property to disrupt the architecture
of lipid rafts. Alterations in lipid rafts by TVB-3166 promote
the mis-localization of membrane-associated oncoproteins,
such as Ras, AKT, and members of the canonical Wnt/β-
catenin pathway. As a consequence, TVB-3166 administration
leads to the abrogation of several signaling cascades and
the induction of tumor cell apoptosis (49). Lu et al.
have synthesized several FASN inhibitors recently using a
structure-based approach guided by X-ray crystallography
approach (51). Among them, compound 34 showed a high
FASN inhibitory potential and favorable pharmacological
features; in addition, it strongly inhibited cell proliferation
in several cancer cell lines including A2780 (ovarian), PC3M
(prostate), LNCaP (prostate), OCI LY1 (lymphoma), MV4-11
(leukemia/lymphoma/myeloma), H460 (lung), A549 (lung), and
MDA-MB-468 (breast), becoming an interesting candidate for
future studies (51).
The synthetic drug IPI-9119, which has been recently
developed, strongly inhibits FASN by promoting acylation of
the catalytic serine, with high selectivity and negligible off-target
activity (52). IPI-9119 was shown able to effectively block
cell growth and proliferation in several cell lines, including
prostatic cancer cells, reducing the proportion of S-phase cells
and increased that of G0/G1 cells, and decreasing expression
of cyclin A2 (52). GSK837149A was identified as a reversible
low inhibitor of the FASN β-ketoacyl reductase domain, but its
poor cell permeability prevented the study of its mechanism
in cells (53), while other synthetic inhibitors like GSK2194069
and JNJ- 54302833 remain to be tested in pre-clinical models.
In addition, several natural plant-derived polyphenols have
been shown to inhibit FASN, including epigallocatechin-3-
gallate (EGCG) and the flavonoids luteolin, taxifolin, kaempferol,
quercetin, and apigenin (54); EGCG in a recent study reduced
the growth of adenocarcinoma human lung cancer xenografts
without inducing body weight loss (37). Other natural FASN
inhibitors may have similar properties, and merit evaluation in
future studies.
Currently, the most promising anti-FASN drug is TVB-
2640, an oral, small-molecule possessing in vitro and in vivo
antitumor activity associated with an acceptable non-clinical
safety profile. Of note, preclinical and early efficacy data from a
dose-escalation trial demonstrated a wide activity of TVB-2640
as a single agent in multiple solid tumors, including cases of
stable disease (clinicaltrials.gov/ct2/show/NCT02223247). These
encouraging results were achieved with relatively low side effects,
which could be eliminated with therapy discontinuation (55).
Currently four further clinical trials are testing TVB-2640 alone
or in combination with other drugs in NSCLC (NCT03808558),
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TABLE 1 | Current evidence on the antineoplastic properties of main FASN inhibitors in cancer.
Name Molecular
formula
Antineoplastic activity and targeted tumor type Current clinical trials References
Cerulenin C12H17NO3 Breast cancer, promyelocytic leukemia and other cells, mouse liver
metastases
– (35, 36)
C75 C14H22O4 Lung cancer cells, radio-sensitization in prostate cancer cells – (37–39)
Orlistat C29H53O5 Prostate, melanoma, breast and other cells, and xenograft tumor
models
– (40–45)
C93 C13H15NO5 Lung, ovarian and trophoblastic neoplasia cells – (46, 47)
Fasnall C19H22N4S·C6H6O3S Breast cancer (combination therapy) – (48)
TVB-3166 C24H24N4O Lung, ovarian, prostate, and pancreatic xenograft tumor models,
combination with taxanes
– (49, 50)
Compound
34
C31H24F3N3O3 Ovarian, prostate, prostate, lymphoma, leukemia, myeloma, lung,
breast cells
(51)
IPI-9119 C24H19F2N5O5 Prostate cancer cells – (52)
GSK837149A C23H22N8O5S2 – – (53)
GSK2194069 C25H24N4O3 – – (35)
JNJ-
54302833
C30H31N5O2 – – (35)
TVB-2640 C27H29N5O Numerous solid tumors, several combinations with
chemotherapeutic agents under evaluation
NCT03808558
NCT02223247
NCT02980029
NCT03179904
NCT03032484
(55)
The code of the clinical trials refers to the ClinicalTrials.gov repository.
colorectal (NCT02980029), breast cancer (NCT03179904), and
astrocytomas (NCT03032484).
TVB-2640 combination treatments are based on evidences
that FASN inhibitors synergize with multiple chemotherapeutic
agents, such as taxanes, vinca alkaloids, 5-fluorouracil, platinum
compounds, and anthracyclines. Furthermore, FASN inhibitors
have been found to restore the sensitivity to chemotherapeutic
drugs, including doxorubicin, and to targeted therapies, such
as those including trastuzumab or lapatinib. In addition, FASN
suppression might also cooperate in radio-sensitization and
with antiangiogenic agents, by triggering strong tumor hypoxia
because cancer cells escape antiangiogenic-driven hypoxia
by upregulation of FASN-related lipogenesis (38, 56). These
evidences strongly suggest that FASN inhibitors will play an
important role in future therapeutic attempts against cancer,
hopefully also against HCC.
CONCLUSION
HCC is a highly aggressive and frequent tumor worldwide, with
its incidence rising also in low-frequency areas. Thus, these
data, together with the lack of effective therapies against this
tumor type, indicate that HCC represents a major health concern
globally. Understanding the intricated molecular pathogenesis
of this cancer entity is therefore necessary for the identification
of specific targets suitable of therapeutic intervention. Recently,
among the potential, novel therapeutic targets identified in
HCC is FASN and the related de novo lipogenesis pathway.
Mounting and solid evidence underscores the fact that aberrant
fatty biosynthesis contributes to hepatocellular carcinogenesis in
experimental models as well as in humans. Albeit several features
of FASN and related lipogenesis remain to be explored, it appears
clear from the data summarized in the present review article that
anti-FASN-based therapies might be helpful for the treatment of
HCC treatment. The use of existing drugs against FASN for the
treatment of HCC (and other tumors) has been impeded by the
low potency and consistent off-target effects of these molecules.
However, the most recent FASN inhibitors (e.g. Fasnall, TVB-
3166, and TVB-2640) seem to have overcome most of these
limitations (56).
Among the critical questions that still need to be addressed
for the clinical practice, is how the HCC patients can be
selected for anti-FASN treatments. It is clear from HCC
TCGA analysis (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.
jsp) as well as other genomic studies (57) that human HCC is
a highly heterogeneous disease. Not all HCCs express FASN and
its related lipogenesis genes at high levels. Consequently, some
HCCs might not depend on FASN and de novo lipogenesis for
growth. This possibility was revealed by in vivo mouse studies.
Indeed, there was no increase in Fasn expression in mouse HCCs
induced by c-Met and gain of function mutant of β-Catenin
(c-Met/β-Catenin) via hydrodynamic injection. Consistently,
ablation of Fasn did not affect HCC growth in mice (35). For this
purpose, reliable biomarkers able to uncover the patients who
would presumably benefit from this therapeutic strategy should
be identified.
Furthermore, as de novo lipogenesis is an integrated part of a
metabolic network, it is conceivable that disruption of fatty acid
synthesis may lead to other biochemical events. These feedback
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FIGURE 3 | Chemical structures of the main FASN inhibitors tested in preclinical and clinical studies.
biochemical and metabolic events may contribute to HCC
development. For instance, in the diethylnitrosamine (DEN)
inducedmouse HCCmodel, inhibition of lipogenesis via deletion
of Acac1 and Acac2 genes in the liver led to an increased HCC
development (58). Mechanistically, this unexpected finding was
due to the marked increased in antioxidants, including increased
NADPH and reduced glutathione, which protected hepatocytes
from oxidant-mediated cell death. In another example, in
murine HCCs induced by overexpression of c-Met and loss
of Pten (c-Met/sgPten), loss of Fasn significantly repressed
HCC formation. However, over long time, HCC lesions could
emerge from Fasn null genetic background. Further molecular
and metabolomic analysis revealed that there was an increased
cholesterol biosynthesis due to increased Srebp2 activity in the
mouse liver tissues. This augmented cholesterogenesis eventually
compensated for the loss of de novo lipogenesis, ultimately
leading to HCC formation (59).
It is also important to acknowledge that two major
mechanisms whereby cells acquire fatty acids required for cell
growth exist: one involves FASN and its mediated de novo
lipogenesis, while the other consists of the transport of circulating
fatty acids via the “lipolytic” pathway (60). This process
requires lipoprotein lipase (LPL), which releases fatty acids from
lipoproteins, as well as fatty acid transporter proteins for fatty
acids uptake (61). The role of exogenous fatty acids during
tumor initiation and progression has been studied marginally
to date. However, recent reports suggested the key role of this
pathway in tumorigenesis. For instance, it was recently found
that fatty acids derived from adipocytes could be transferred
to melanoma cells through the fatty acid transporter protein
SLC27A1. Blocking fatty acid uptake via the fatty acid transport
proteins inhibitor Lipofermata significantly reduced melanoma
growth and invasion (62). In HCC cells, it has been shown that
LPL mediated fatty acid uptake could at least partly compensate
the blockade of de novo lipogenesis (63). These studies indicate
that presumably both de novo fatty acid synthesis and exogenous
fatty acid uptake should be inhibited to achieve significant anti-
cancer effects.
In addition, future studies are required to determine
whether anti-FASN drugs can be used in combination with
FDA-approved anti-HCC multi-kinase inhibitors (Sorafenib,
Regorafenib, Cabozantinib), immune modulators (checkpoint
inhibitors), and/or conventional chemotherapeutic drugs for the
treatment of HCC. Studies to address this important point should
be conducted. An alternative approach to suppress FASN in
HCC (and other tumor types) could be the inhibition of FASN
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upstream inducers, such as USP2a and CD147. As concerns
USP2a, ML364, a small molecule inhibitor of this deubiquitinase
has been recently developed. Of note, ML364 administration
caused cell cycle arrest in colorectal cancer and lymphoma
cell lines, although the specific effect of the drug on FASN
levels was not investigated (64). Preliminary results obtained
in our laboratory indicate a strong growth restraint as well
as downregulation of FASN in HCC cell lines treated with
ML364 (Cigliano et al., unpublished observation), suggesting
that inhibition of USP2a might be a promising therapy for
this deadly disease. Furthermore, targeting CD147 has revealed
promising results in the treatment of human HCC patients.
Indeed, HCC recurrence rate was found to be significantly
decreased, and the survival length of HCC patients subjected to
liver transplantation prolonged, following the administration of a
monoclonal antibody against CD147, in a randomized controlled
trial (65).
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